(PDF) P3.13-13 Afatinib in Lung Adenocarcinoma Harboring De

P3.13-13 Afatinib in Lung Adenocarcinoma Harboring De Novo EGFR Exon 20 Insertions.

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1853

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma

Clinical Cancer Research

Cancer Research

English

OA07 Clinical Characterization of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes to Afatinib in Chinese Lung Cancers

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-61 Clinical Characterization of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes to Afatinib in Chinese Lung Cancers

Journal of Thoracic Oncology

Respiratory Medicine

English

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

Cancer Research

English

P3.cr-12 a Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib

Journal of Thoracic Oncology

Respiratory Medicine

English

Lung Adenocarcinoma Manifesting With Lymphangitic Spread and Psammoma Bodies, Harboring a HER2 Exon 20 Insertion Mutation (p.A745_G746insYVMA)

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.13-12 a Lung Adenocarcinoma With Concomitant EGFR and De Novo MET Amplification Response Well to Combination of TKI and Bevacizumab

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-96 Clinical Characteristics of Non–Small Cell Lung Cancer Harboring Mutations in Exon 20 of EGFR or HER2

Journal of Thoracic Oncology

Respiratory Medicine

English

Two Sides of the Same Coin: EGFR Exon 19 Deletions and Insertions in Lung Cancer

Clinical Cancer Research

Cancer Research

English